Prevalence of actionable mutations and copy number alterations and the price of a genomic testing panel.

ABSTRACT: Interest in genomic testing for the selection of cancer therapy is growing. However, the cost of genomic testing has not been well studied. We sought to determine the price of identifying mutations and copy number alterations (CNAs) in theoretically actionable genes across multiple tumor types. We reviewed data from The Cancer Genome Atlas to determine the frequency of alterations in nine tumor types. We used price information from a commonly used commercial genomic testing platform (FoundationOne) to determine the price of detecting mutations and CNAs in different types of tumors. Although there are large variations in the prevalence by tumor type, when the detection of both mutations and CNAs was considered overall, most patients had at least one alteration in a potentially actionable ge

SUBMITTER: Shen C 

PROVIDER: S-EPMC5342111 | biostudies-literature | 2016 Nov

REPOSITORIES: biostudies-literature